Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

The anaphylatoxin C5a is an especially potent mediator of both local and systemic inflammation. However, C5a also plays an essential role in mucosal host defense against bacterial, viral, and fungal infection. We have developed a response-selective agonist of human C5a, termed EP67, which retains th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sam D Sanderson, Marilyn L Thoman, Kornelia Kis, Elizabeth L Virts, Edgar B Herrera, Stephanie Widmann, Homero Sepulveda, Joy A Phillips
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4a5b73a79a904400aed8a1153e0929ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4a5b73a79a904400aed8a1153e0929ea
record_format	dspace
spelling	oai:doaj.org-article:4a5b73a79a904400aed8a1153e0929ea2021-11-18T07:13:13ZInnate immune induction and influenza protection elicited by a response-selective agonist of human C5a.1932-620310.1371/journal.pone.0040303https://doaj.org/article/4a5b73a79a904400aed8a1153e0929ea2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22792270/?tool=EBIhttps://doaj.org/toc/1932-6203The anaphylatoxin C5a is an especially potent mediator of both local and systemic inflammation. However, C5a also plays an essential role in mucosal host defense against bacterial, viral, and fungal infection. We have developed a response-selective agonist of human C5a, termed EP67, which retains the immunoenhancing activity of C5a at the expense of its inflammatory, anaphylagenic properties. EP67 insufflation results in the rapid induction of pulmonary cytokines and chemokines. This is followed by an influx of innate immune effector cells, including neutrophils, NK cells, and dendritic cells. EP67 exhibits both prophylactic and therapeutic protection when tested in a murine model of influenza A infection. Mice treated with EP67 within a twenty-four hour window of non-lethal infection were significantly protected from influenza-induced weight loss. Furthermore, EP67 delivered twenty-four hours after lethal infection completely blocked influenza-induced mortality (0% vs. 100% survival). Since protection based on innate immune induction is not restricted to any specific pathogen, EP67 may well prove equally efficacious against a wide variety of possible viral, bacterial, and fungal pathogens. Such a strategy could be used to stop the worldwide spread of emergent respiratory diseases, including but not limited to novel strains of influenza.Sam D SandersonMarilyn L ThomanKornelia KisElizabeth L VirtsEdgar B HerreraStephanie WidmannHomero SepulvedaJoy A PhillipsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 7, p e40303 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sam D Sanderson Marilyn L Thoman Kornelia Kis Elizabeth L Virts Edgar B Herrera Stephanie Widmann Homero Sepulveda Joy A Phillips Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
description	The anaphylatoxin C5a is an especially potent mediator of both local and systemic inflammation. However, C5a also plays an essential role in mucosal host defense against bacterial, viral, and fungal infection. We have developed a response-selective agonist of human C5a, termed EP67, which retains the immunoenhancing activity of C5a at the expense of its inflammatory, anaphylagenic properties. EP67 insufflation results in the rapid induction of pulmonary cytokines and chemokines. This is followed by an influx of innate immune effector cells, including neutrophils, NK cells, and dendritic cells. EP67 exhibits both prophylactic and therapeutic protection when tested in a murine model of influenza A infection. Mice treated with EP67 within a twenty-four hour window of non-lethal infection were significantly protected from influenza-induced weight loss. Furthermore, EP67 delivered twenty-four hours after lethal infection completely blocked influenza-induced mortality (0% vs. 100% survival). Since protection based on innate immune induction is not restricted to any specific pathogen, EP67 may well prove equally efficacious against a wide variety of possible viral, bacterial, and fungal pathogens. Such a strategy could be used to stop the worldwide spread of emergent respiratory diseases, including but not limited to novel strains of influenza.
format	article
author	Sam D Sanderson Marilyn L Thoman Kornelia Kis Elizabeth L Virts Edgar B Herrera Stephanie Widmann Homero Sepulveda Joy A Phillips
author_facet	Sam D Sanderson Marilyn L Thoman Kornelia Kis Elizabeth L Virts Edgar B Herrera Stephanie Widmann Homero Sepulveda Joy A Phillips
author_sort	Sam D Sanderson
title	Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
title_short	Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
title_full	Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
title_fullStr	Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
title_full_unstemmed	Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
title_sort	innate immune induction and influenza protection elicited by a response-selective agonist of human c5a.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/4a5b73a79a904400aed8a1153e0929ea
work_keys_str_mv	AT samdsanderson innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a AT marilynlthoman innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a AT korneliakis innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a AT elizabethlvirts innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a AT edgarbherrera innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a AT stephaniewidmann innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a AT homerosepulveda innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a AT joyaphillips innateimmuneinductionandinfluenzaprotectionelicitedbyaresponseselectiveagonistofhumanc5a
_version_	1718423783523483648

Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Ejemplares similares